These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Renal Clearable Bi-Bi2S3 Heterostructure Nanoparticles for Targeting Cancer Theranostics.
    Author: Dong L, Zhang P, Liu X, Deng R, Du K, Feng J, Zhang H.
    Journal: ACS Appl Mater Interfaces; 2019 Feb 27; 11(8):7774-7781. PubMed ID: 30698406.
    Abstract:
    Recent development of precise nanomedicine has aroused an overwhelming interest in integration of diagnosis and treatment for cancers. Designing renal-clearable and targeting nanoparticles (NPs) has specific cancer theranostic implications and remains a challenging task. In this work, the ultrasmall folic acid (FA) and bovine serum albumin-modified Bi-Bi2S3 heterostructure nanoparticles NPs (Bi-Bi2S3/BSA&FA NPs) with excellent computed tomography (CT) and photoacoustic imaging abilities and outstanding photothermal performances were synthesized in an aqueous phase route via a simple method. Bi-Bi2S3/BSA&FA NPs have the following criteria: (i) Bi-Bi2S3/BSA&FA NPs with heterostructure possess better stability than Bi NPs and higher Bi content than Bi2S3 NPs, which are conducive to the enhancement of CT imaging effect; (ii) Bi-Bi2S3/BSA&FA NPs with FA molecules on the surface could target the tumor site effectively; (iii) Bi-Bi2S3/BSA&FA NPs could inhibit tumor growth effectively under 808 nm laser irradiation; (iv) ultrasmall Bi-Bi2S3/BSA&FA NPs could be cleared through kidney and liver within a reasonable time, avoiding a long-term retention/toxicity. Therefore, the renal clearable Bi-Bi2S3/BSA&FA NPs are a promising agent for targeting cancer theranostics.
    [Abstract] [Full Text] [Related] [New Search]